105910-05-2 Usage
Uses
Used in Pharmaceutical Synthesis:
(E)-ethyl 3-(4-methyl-2-nitrophenyl)acrylate is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, (E)-ethyl 3-(4-methyl-2-nitrophenyl)acrylate serves as a crucial building block for the creation of effective pesticides and other agricultural chemicals, contributing to enhanced crop protection and yield.
Used in Polymer and Resin Manufacturing:
(E)-ethyl 3-(4-methyl-2-nitrophenyl)acrylate is utilized as a monomer in the production of polymers and resins, which are essential components in a wide range of industrial applications, including coatings, adhesives, and composite materials.
Used in Coating and Adhesive Formulation:
(E)-ethyl 3-(4-methyl-2-nitrophenyl)acrylate is also used as a component in the formulation of coatings and adhesives, where its chemical properties contribute to improved performance, durability, and bonding strength.
It is important to handle (E)-ethyl 3-(4-methyl-2-nitrophenyl)acrylate with care due to potential health and safety hazards if not used properly.
Check Digit Verification of cas no
The CAS Registry Mumber 105910-05-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,5,9,1 and 0 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 105910-05:
(8*1)+(7*0)+(6*5)+(5*9)+(4*1)+(3*0)+(2*0)+(1*5)=92
92 % 10 = 2
So 105910-05-2 is a valid CAS Registry Number.
105910-05-2Relevant articles and documents
COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE
-
Page/Page column 142-143, (2009/04/25)
Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121)
Bonfanti, Jean-Fran?ois,Meyer, Christophe,Doublet, Frédéric,Fortin, Jér?me,Müller, Philippe,Queguiner, Laurence,Gevers, Tom,Janssens, Peggy,Szel, Heidi,Willebrords, Rudy,Timmerman, Philip,Wuyts, Koen,Van Remoortere, Pieter,Janssens, Frans,Wigerinck, Piet,Andries, Koen
, p. 875 - 896 (2008/09/19)
A preceding paper (Bonfanti et al. J. Med Chem. 2007, 50, 4572-4584) reported the optimization of the pharmacokinetic profile of substituted benzimidazoles by reducing their tissue retention. However, the modifications that were necessary to achieve this goal also led to a significant drop in anti-RSV activity. This paper describes a molecular modeling study followed by a lead optimization program that led to the recovery of the initial potent antiviral activity and the selection of TMC353121 as a clinical candidate.